They showed that advanced stage ALK-altered histiocytosis patients including those with neurological disease can be effectively treated with ALK inhibitors (11/11 objective and sustained response were achieved with ALK inhibitors such as crizotinib, alectinib, brigatinib and lorlatinib in first, second or further line setting74). The gene discussed is ALK; the disease is Histiocytosis.